Vima banks $100m in Series A to progress Parkinson’s drug
The selective muscarinic antagonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.
PRISM BioLab partners with Receptor.AI for molecule discovery
PsiQuantum and National Cancer Center Japan partner on quantum computing
Eli Lilly finds impurity in compounded tirzepatide
Curatis and Neupharma sign development agreement for corticorelin in Japan
Bavarian Nordic and SII sign agreement for chikungunya vaccine production
Analysis
View More
Themes
View MoreCinnaGen Enters EU Market with EMA Approval for Zandoriah®
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?